Total Payments
$82,360
2024 Payments
$9,294
Companies
33
Transactions
568
Medicare Patients
595
Medicare Billing
$2.3M
Payment Breakdown by Category
Other$32,039 (38.9%)
Consulting$16,713 (20.3%)
Food & Beverage$14,373 (17.5%)
Research$12,385 (15.0%)
Gifts$4,190 (5.1%)
Travel$2,395 (2.9%)
Education$265.54 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,154 | 8 | 28.1% |
| Consulting Fee | $16,713 | 11 | 20.3% |
| Food and Beverage | $14,373 | 498 | 17.5% |
| Unspecified | $12,385 | 17 | 15.0% |
| Honoraria | $8,651 | 4 | 10.5% |
| Gift | $4,190 | 1 | 5.1% |
| Travel and Lodging | $2,395 | 16 | 2.9% |
| Education | $265.54 | 12 | 0.3% |
| Debt forgiveness | $233.82 | 1 | 0.3% |
Payments by Type
General
$69,975
551 transactions
Research
$12,385
16 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $20,295 | 61 | $0 (2019) |
| ADMA BioManufacturing LLC | $8,905 | 35 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $7,830 | 21 | $0 (2022) |
| Blueprint Medicines Corporation | $7,626 | 17 | $0 (2024) |
| Pharming Healthcare, Inc. | $5,983 | 24 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,952 | 56 | $0 (2024) |
| CSL Behring | $4,903 | 106 | $0 (2024) |
| Consortium of Independent Immunology Clinics, LLC | $4,400 | 3 | $0 (2024) |
| Olympus America Inc. | $4,190 | 1 | $0 (2019) |
| Grifols USA, LLC | $2,836 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,294 | 69 | Consortium of Independent Immunology Clinics, LLC ($4,400) |
| 2023 | $23,224 | 123 | ADMA BioManufacturing LLC ($8,544) |
| 2022 | $3,778 | 74 | Blueprint Medicines Corporation ($1,542) |
| 2021 | $4,885 | 74 | Takeda Pharmaceuticals U.S.A., Inc. ($3,668) |
| 2020 | $6,693 | 46 | BioCryst Pharmaceuticals, Inc. ($2,272) |
| 2019 | $25,949 | 92 | Shire North American Group Inc ($13,024) |
| 2018 | $1,098 | 53 | Shire North American Group Inc ($427.97) |
| 2017 | $7,439 | 37 | Shire North American Group Inc ($6,843) |
All Payment Transactions
568 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: Immunology | ||||||
| 12/17/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: Immunology | ||||||
| 11/19/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $25.26 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.58 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | Octapharma USA, Inc. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: Respiratory | ||||||
| 10/22/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: Immunology | ||||||
| 10/22/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Immunology | ||||||
| 10/10/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $30.34 | General |
| Category: Oncology / Rare Diseases | ||||||
| 09/16/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Immunology | ||||||
| 09/13/2024 | CSL Behring | — | Food and Beverage | In-kind items and services | $134.99 | General |
| 09/12/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $18.60 | General |
| 09/10/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: Immunology | ||||||
| 09/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: GENETIC DISEASE | ||||||
| 09/09/2024 | PFIZER INC. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Drug), PANZYGA, CUTAQUIG | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: IMMUNOLOGY | ||||||
| 09/03/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Immunology | ||||||
| 08/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $24.71 | General |
| Category: IMMUNOLOGY | ||||||
| 08/26/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $30.18 | General |
| Category: IMMUNOLOGY | ||||||
| 08/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $24.84 | General |
| Category: Respiratory | ||||||
| 08/13/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Immunology | ||||||
| 07/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Food and Beverage | In-kind items and services | $28.23 | General |
| Category: GENETIC DISEASE | ||||||
| 07/29/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $25.46 | General |
| 07/10/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 84 | 16,026 | $2.5M | $697,406 |
| 2022 | 7 | 94 | 796 | $88,270 | $23,982 |
| 2021 | 14 | 222 | 17,822 | $2.7M | $816,912 |
| 2020 | 11 | 195 | 22,518 | $3.4M | $729,419 |
Total Patients
595
Total Services
57,162
Medicare Billing
$2.3M
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2023 | 11 | 6,460 | $1.0M | $359,703 | 35.9% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 15 | 8,750 | $1.4M | $312,009 | 23.0% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 17 | 553 | $36,166 | $8,852 | 24.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 17 | 175 | $37,333 | $8,828 | 23.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 88 | $27,105 | $8,014 | 29.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 13 | 511 | $33,419 | $8,815 | 26.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 13 | 151 | $32,213 | $8,392 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 66 | $20,329 | $6,342 | 31.2% |
| 94016 | Test to measure expiratory airflow and volume initiated by patient and evaluated by provider | Office | 2022 | 11 | 13 | $1,095 | $238.08 | 21.7% |
| 94640 | Inhalation treatment for airway obstruction or sputum production | Office | 2022 | 11 | 13 | $622.83 | $109.26 | 17.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 14 | 29 | $435.00 | $85.32 | 19.6% |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 2022 | 11 | 13 | $156.00 | $0.37 | 0.2% |
| J1556 | Injection, immune globulin (bivigam), 500 mg | Office | 2021 | 14 | 8,570 | $1.3M | $486,071 | 36.6% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2021 | 15 | 8,220 | $1.3M | $294,288 | 23.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis | Office | 2021 | 16 | 567 | $37,082 | $10,311 | 27.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 16 | 167 | $35,626 | $10,000 | 28.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 76 | $23,409 | $7,560 | 32.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 49 | $10,177 | $3,201 | 31.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 13 | 18 | $7,461 | $2,652 | 35.5% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 15 | 25 | $4,571 | $959.50 | 21.0% |
| 94016 | Physician interpretation and report of measurement and graphic recording of amount and speed of breathed air over 30-day period | Office | 2021 | 16 | 27 | $2,274 | $548.37 | 24.1% |
| 95012 | Measurement of inhaled nitric oxide gas | Office | 2021 | 15 | 27 | $1,620 | $444.96 | 27.5% |
| 90674 | Vaccine for influenza derived from cell cultures for administration into muscle, 0.5 ml dosage, quadrivalent, , preservative and antibiotic free | Office | 2021 | 13 | 13 | $1,170 | $389.22 | 33.3% |
| 94640 | Respiratory inhaled pressure or nonpressure treatment to relieve airway obstruction or for sputum specimen | Office | 2021 | 16 | 24 | $1,150 | $278.64 | 24.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 12 | 12 | $222.00 | $208.32 | 93.8% |
About Dr. Daniel Suez, MD
Dr. Daniel Suez, MD is a Allergy & Immunology healthcare provider based in Irving, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1255312773.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Suez, MD has received a total of $82,360 in payments from pharmaceutical and medical device companies, with $9,294 received in 2024. These payments were reported across 568 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($23,154).
As a Medicare-enrolled provider, Suez has provided services to 595 Medicare beneficiaries, totaling 57,162 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Irving, TX
- Active Since 11/10/2005
- Last Updated 07/08/2007
- Taxonomy Code 207K00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255312773
Products in Payments
- HYQVIA (Biological) $19,559
- Bivigam (Drug) $8,385
- CINQAIR (Biological) $7,662
- CUVITRU (Biological) $4,425
- Olympus Capital Accessories (Device) $4,190
- JOENJA (Drug) $3,464
- Xembify (Biological) $2,612
- AYVAKIT (Drug) $1,617
- Hizentra (Biological) $1,279
- DUPIXENT (Biological) $996.43
- Haegarda (Biological) $760.13
- ORLADEYO (Drug) $710.66
- TAKHZYRO (Biological) $683.78
- RUCONEST (Biological) $518.92
- FASENRA (Biological) $472.29
- NUCALA (Biological) $445.47
- Xhance (Drug) $297.37
- CINRYZE (Drug) $260.63
- PANZYGA (Biological) $227.61
- Gamunex-C (Biological) $224.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.